A Phase 2 interventional study of DFN-15 (Celecoxib Oral Solution) 62.5 mg and DFN-15 (Celecoxib Oral Solution) 125 mg in Acute Pain, sponsored by Dr. Reddy's Laboratories Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-01-22.
Sponsored by Dr. Reddy's Laboratories Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 351 studies in Acute Pain with a site in United States — 47 open to participants now, 53 under way, 1 of them phase 3. Acute Pain · United States.
Among the 351 studies in Acute Pain with a site in United States, this one is the 117th largest by enrollment of the 320 interventional ones that give a count, is one of 34 that started in 2018, is one of 54 in phase 2, and was the 137th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →47 of the 351 studies in Acute Pain with a site in United States are open now. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Aponia Laboratories, Inc. · Sites in United States, Germany
Ages 18–65
Florida State University · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States
Ages 18–40
Ochsner Health System · Sites in United States
Ages 35+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
351 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 63 · Phase 3 48 · Phase 4 66
First in 2001; this study’s year is marked. 34 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 84 across the 320 interventional studies, 100 across the 31 observational. Of the 265 that completed or were terminated, 132 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
78 of 351 have an industry lead sponsor. The 10 most frequent:
Dr. Reddy's Laboratories Limited is the lead sponsor of 224 studies on the registry; 2 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 11 (85%) have results posted.
Dr. Reddy's Laboratories Limited has 1 study filed under Acute Pain — fewer than ten, so there is no comparison to draw.
31 of the studies in Acute Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07930559Phase 3Aponia Laboratories, Inc.Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions | 2027-06 |
| NCT07511816Eli Lilly and CompanyA Study of LY4515100 in Participants With Pain Following Third Molar Removal | 2026-11 |
| NCT05335070Rutgers, The State University of New JerseyReducing Pain From Wisdom Molar Extractions | 2026-11 |
| NCT06795126Nationwide Children's HospitalLittle NIRVANA for Pediatric Pain and Anxiety | 2026-11-30 |
| NCT05458037Women and Infants Hospital of Rhode IslandRCT of Pain Perception With Fast and Slow Tenaculum Application | 2026-12 |
Add all 31 to your calendar (.ics) → With an account.
Among the 351 studies in Acute Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Efficacy, Tolerability, Safety and Pharmacokinetic Study of DFN-15 in Post-Surgical Dental Pain.
This is a Phase 2, single-center, randomized, double blind, dose-ranging placebo-controlled, clinical study evaluating the efficacy, tolerability, safety, and the pharmacokinetic properties of a known drug (selective COX-2 inhibitor) administered as an alternative formulation/dosage form (DFN-15, a liquid oral formulation) in an accepted model of acute post-operative pain (acute pain following oral surgery for extraction of bilateral impacted mandibular third molar teeth in otherwise healthy subjects).120 female and male healthy subjects scheduled to undergo elective bilateral third molar extraction will be randomized, after they provide informed consent and are confirmed to meet all the study selection criteria, in a 1:1:1:1 ratio to receive a single oral dose of either DFN-15 Dose A DFN-15 Dose B, DFN-15 Dose C or matching placebo.
Subjects will undergo a screening procedure (within 28 days of the scheduled extraction of the impacted third molars) that will involve the collection of demographic information, height, weight and body mass index (BMI), urine pregnancy test (women of child-bearing potential,) medical and medicinal history, physical examination, dental examination, vital signs measurement (blood pressure, pulse rate, respiratory rate), clinical laboratory investigation (hematology,serology, coagulation parameters, serum chemistry and urinalysis),12-lead ECG and a panoramic x-ray to document the impacted mandibular third molar teeth. As a pre-requisite for randomization, subjects will be required to report "moderate" to "severe" baseline pain on the provided paper diary within 6 hours post-surgery (called the 'Baseline' period) as characterized on a 4-point categorical pain intensity (PI) scale (0= none, 1= mild, 2= moderate, 3= severe), and a score of ≥5, on the 11-point Numerical Pain Rating Scale (NPRS) where 0 represents 'no pain' and 10 represents 'worst pain imaginable'. Eligible subjects will be randomized and will receive a single dose of the assigned study treatment. Subjects will be randomized and administered the study medication within 15 minutes of meeting the post-operative inclusion criteria (baseline score).Subjects will be assessed at pre-specified time-points over an observation period of 8 hours from the time of randomization.
Subjects with inadequately controlled pain symptoms may request rescue analgesic medication. Subjects will be encouraged to delay using the rescue medication if their pain is tolerable until 120 minutes post-dose of study medication. A subject who is administered rescue pain medication will continue completing pain assessments until 8 hours after treatment initiation. All randomized subjects will be provided with a paper diary to record pain assessments (Pain Intensity on 11-point NPRS scale, followed by Pain Relief using a 5-point categorical scale [where 0= no pain relief, 1= little pain relief, 2= some pain relief, 3= a lot of pain relief, 4= complete pain relief]) At study medication administration, two stopwatches will be started, to measure times to 'perceptible' and 'meaningful' pain-relief. Subjects will be instructed to stop the first stopwatch when they first perceive pain relief to occur (time to perceptible relief). Subjects will be instructed to stop the second stopwatch when they first experience meaningful pain relief (time to meaningful relief). Stopwatch times of perceptible relief and meaningful relief will be recorded using exact stopwatch time displayed.
In addition, at 8 hours post-dose or within 5 minutes prior to first use of rescue medication (whichever is earlier), subjects will be asked to record within the provided patient diary: 'Patient Rating of Treatment Satisfactoriness' using a 5-point verbal rating scale (0 =poor, 1 =fair, 2 =good, 3=very good, 4 =excellent).
Subjects will remain NPO (nothing by mouth), including water, from Check-in (i.e., at least 2 hours before the administration of the dose of study medication to randomized subjects) until 2 hours post-dose, on Day 1 (study day). After 2 hours post-dose, subjects may be permitted to consume water, or gelatin snacks. Subjects are prohibited from ingesting solid foods or carbonated beverages for at least 6 hours post-dose.
12-lead ECG and Vital Signs were performed before surgery, at baseline and at periodic intervals post-dose until 8 hours .At discharge (8 hours post-randomization) from the clinical facility, all AEs reported for the subjects will be reviewed. A physical examination, including evaluation of the incision site for hematomas, and clinical laboratory evaluation (coagulation parameters and specific hematology, serum biochemistry and urinalysis parameters) will be conducted.
All subjects will have blood drawn at specified time points (pre-dose and over the 8 hour observation period) for pharmacokinetic evaluation.
Subjects will return to the research center 7 days (± 3 days) post-surgery for evaluation of their safety and well-being. Any AEs experienced post-surgery will be reviewed. A physical examination, of the subject will be performed, 12-lead ECG, and vital signs parameters will be repeated. Hematology, coagulation parameters, serum biochemistry and urinalysis parameters will be repeated only if there is a clinically significant abnormality or ongoing AE(s). Any changes to the prior and concomitant medication made after discharge will be reviewed and recorded.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose containing 62.5 mg of celecoxib in 10 ml solution
Drug: DFN-15 (Celecoxib Oral Solution) 62.5 mg
Single dose containing 125 mg of celecoxib in 10 ml solution
Drug: DFN-15 (Celecoxib Oral Solution) 125 mg
Single dose containing 250 mg of celecoxib in 10 ml solution
Drug: DFN-15 (Celecoxib Oral Solution) 250 mg
Single dose containing 0 mg of celecoxib in 10 ml solution
Drug: Placebo
Oral Solution
Oral Solution
Oral Solution
Oral Solution
Summed Pain Intensity Difference Over the First Six Hours
The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable. SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)\^x▒((〖PID〗_i+〖PID〗_(i+1))/2) \* (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1. Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)
Time frame: 6 hours post dose
| Milestone | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg |
|---|---|---|---|---|
| Started | 30 | 30 | 29 | 31 |
| Completed treatment period (8 hours post dose) | 30 | 30 | 29 | 31 |
| Completed | 30 | 30 | 29 | 29 |
| Not completed | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 |
The primary endpoint is the Summed Pain Intensity Difference over the first 6 hours (SPID6) after dosing compared between DFN-15 and placebo. Pain intensity (P) will be measured at timepoints of 15, 30, and 45 minutes and 1, 1.5, 2, 3, 4, 5 and 6, hours after baseline ,using 11-point Pain Intensity Numerical Rating Scale (NPRS). Zero (0) equals no pain and Ten (10) equals worst pain imaginable. SPID6 is created by summing the time weighted pain intensity differences (PID) scores using the area under the PID curve methodology. All SPID calculations will be performed using the standard trapezoidal rule SPIDx =∑_(i=0)\^x▒((〖PID〗_i+〖PID〗_(i+1))/2) \* (T_(i+1)- T_i ) Where: PID_i = P_i - PBL (Pain score at time i and Pain score at Baseline), and (T_i+1 - T_i) is the Time difference in minutes between time i and time i+1. Therefore, SPID6 values may theoretically range between a maximum score of 0 ( no improvement) and a minimum score of -3525 (best improvement)
| units on a scale | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg |
|---|---|---|---|---|
| Summed Pain Intensity Difference Over the First Six Hours | -420.2 ± 716.42 | -1101.0 ± 570.74 | -1771.7 ± 646.10 | -1463.5 ± 727.28 |
Collected over All AEs, whether volunteered, elicited, or noted on physical examination, and regardless of causality or seriousness, were assessed and recorded in the CRF beginning after administration of study drug through the final follow-up assessment (approximately 7 ± 3 days after the last study drug administration). Additionally, if the investigator became aware of the occurrence of an SAE within 30 days of the last visit, the SAE was reported.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/30 (0%) | 0/30 (0%) | 4/30 (13.3%) |
| DFN-15 (Celecoxib Oral Solution) 62.5 mg | 0/30 (0%) | 0/30 (0%) | 5/30 (16.7%) |
| DFN-15 (Celecoxib Oral Solution) 125 mg | 0/29 (0%) | 0/29 (0%) | 4/29 (13.8%) |
| DFN-15 (Celecoxib Oral Solution) 250 mg | 0/31 (0%) | 0/31 (0%) | 5/31 (16.1%) |
| Event | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/30 | 2/30 | 1/29 | 1/31 |
| Blood Bilirubin IncreasedInvestigations | 0/30 | 1/30 | 0/29 | 2/31 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 0/30 | 0/30 | 0/29 | 2/31 |
| DizzinessNervous system disorders | 1/30 | 0/30 | 1/29 | 0/31 |
| Alveolar OsteitisInfections and infestations | 1/30 | 0/30 | 1/29 | 0/31 |
| Wolff-Parkinson-White syndromeCardiac disorders | 0/30 | 0/30 | 1/29 | 0/31 |
| VomitingGastrointestinal disorders | 1/30 | 1/30 | 0/29 | 1/31 |
| Blood Creatinine increasedInvestigations | 1/30 | 0/30 | 0/29 | 0/31 |
| Blood Urine PresentInvestigations | 0/30 | 1/30 | 0/29 | 0/31 |
| Cardiac MurmurInvestigations | 0/30 | 1/30 | 0/29 | 0/31 |
| Age, Continuous(years) | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg | Total |
|---|---|---|---|---|---|
| Mean | 19.9 ± 2.70 | 19.6 ± 2.45 | 19.2 ± 1.64 | 20.5 ± 2.45 | 19.8 ± 2.37 |
| Sex: Female, Male(Participants) | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg | Total |
|---|---|---|---|---|---|
| Female | 16 | 14 | 17 | 13 | 60 |
| Male | 14 | 16 | 12 | 18 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 4 | 7 | 23 |
| Not Hispanic or Latino | 24 | 24 | 25 | 24 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 1 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 2 | 0 | 3 |
| Black or African American | 1 | 1 | 0 | 0 | 2 |
| White | 28 | 26 | 22 | 28 | 104 |
| More than one race | 0 | 1 | 2 | 1 | 4 |
| Unknown or Not Reported | 0 | 1 | 2 | 2 | 5 |
| BMI(kg/ m^2) | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg | Total |
|---|---|---|---|---|---|
| Mean | 26.4 ± 4.15 | 27.1 ± 5.03 | 25.1 ± 4.11 | 24.4 ± 4.41 | 25.8 ± 4.51 |
| Qualifying Baseline Categorical Pain Score(Participants) | Placebo | DFN-15 (Celecoxib Oral Solution) 62.5 mg | DFN-15 (Celecoxib Oral Solution) 125 mg | DFN-15 (Celecoxib Oral Solution) 250 mg | Total |
|---|---|---|---|---|---|
| 0 = No Pain | 0 | 0 | 0 | 0 | 0 |
| 1= Mild Pain | 0 | 0 | 0 | 0 | 0 |
| 2= Moderate Pain | 8 | 13 | 11 | 12 | 44 |
| 3= Severe Pain | 22 | 17 | 18 | 19 | 76 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Aug 2018, 2 months.
Results were first posted in Jan 2021, 2 years 5 months after primary completion. A results delay was requested in Sep 2019.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Celecoxib
Dr. Reddy's Laboratories Limited →